Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...
Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...
The marketing authorization application for KEYTRUDA SC is based on results from the pivotal 3475A-D77 trial comparing KEYTRUDA SC and KEYTRUDA administered every six weeks, each with chemotherapy, ...
The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...
SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck ...
What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
For the better part of a year, Merck & Co. and Halozyme have been locked in an intellectual property disagreement over the the pharma giant's new, under-the-skin version of cancer megablockbuster ...
Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback